Abstract: This disclosure relates to compositions including formulated sucralfate or other aluminum-crosslinked sulfated agents for delivery of agents to biological surfaces and/or the modulation of nutrient absorption through the intestinal lining as well as methods for the manufacture of and the use of these compositions for treating disorders including diabetes type II and clinical obesity that require a modulation of certain nutrients to the body.

Abstract: Compositions formulated for release within the gastrointestinal tract and related methods are discussed. The composition may include a mucoadhesive agent and an active agent. The composition may be formulated for release of the active agent in a first direction while inhibiting release of the active agent in a second direction opposite the first direction.

Abstract: This disclosure relates to compositions including formulated sucralfate or other aluminum-crosslinked sulfated agents for delivery of agents to biological surfaces and/or the modulation of nutrient absorption through the intestinal lining as well as methods for the manufacture of and the use of these compositions for treating disorders including diabetes type II and clinical obesity that require a modulation of certain nutrients to the body.

Abstract: This disclosure relates to compositions including formulated sucralfate or other aluminum-crosslinked sulfated agents for the modulation of nutrient absorption through the intestinal lining as well as methods for the manufacture of and the use of these compounds for treating disorders requiring a modulation of certain nutrients to the body including diabetes type II and clinical obesity.

Abstract: This disclosure relates to compositions including formulated sucralfate or other aluminum-crosslinked sulfated agents for the modulation of nutrient absorption through the intestinal lining as well as methods for the manufacture of and the use of these compounds for treating disorders requiring a modulation of certain nutrients to the body including diabetes type II and clinical obesity.

Abstract: This disclosure relates to compositions including formulated sucralfate or other aluminum-crosslinked sulfated agents for delivery of agents to biological surfaces and/or the modulation of nutrient absorption through the intestinal lining as well as methods for the manufacture of and the use of these compositions for treating disorders including diabetes type II and clinical obesity that require a modulation of certain nutrients to the body.

Abstract: This disclosure relates to compositions including formulated sucralfate or other aluminum-crosslinked sulfated agents for delivery of agents to biological surfaces and/or the modulation of nutrient absorption through the intestinal lining as well as methods for the manufacture of and the use of these compositions for treating disorders including diabetes type II and clinical obesity that require a modulation of certain nutrients to the body.

Abstract: This disclosure relates to compositions including formulated sucralfate or other aluminum-crosslinked sulfated agents and one or more biologically active substances to mucosal surfaces within the GI tract and methods for the manufacture and the use of these compositions.

Abstract: This disclosure relates to compositions including formulated sucralfate or other aluminum-crosslinked sulfated agents for delivery of agents to biological surfaces and/or the modulation of nutrient absorption through the intestinal lining as well as methods for the manufacture of and the use of these compositions for treating disorders including diabetes type II and clinical obesity that require a modulation of certain nutrients to the body.

Abstract: This disclosure relates to compositions including formulated sucralfate or other aluminum-crosslinked sulfated agents for delivery of agents to biological surfaces and/or the modulation of nutrient absorption through the intestinal lining as well as methods for the manufacture of and the use of these compositions for treating disorders including diabetes type II and clinical obesity that require a modulation of certain nutrients to the body.

Abstract: This disclosure relates to compositions including formulated sucralfate or other aluminum-crosslinked sulfated agents for the modulation of nutrient absorption through the intestinal lining as well as methods for the manufacture of and the use of these compounds for treating disorders requiring a modulation of certain nutrients to the body including diabetes type II and clinical obesity.

Abstract: This disclosure relates to compositions including formulated sucralfate or other aluminum-crosslinked sulfated agents for the modulation of nutrient absorption through the intestinal lining as well as methods for the manufacture of and the use of these compounds for treating disorders requiring a modulation of certain nutrients to the body including diabetes type II and clinical obesity.

Abstract: This disclosure relates to compositions including formulated sucralfate or other aluminum-crosslinked sulfated agents for delivery of agents to biological surfaces and/or the modulation of nutrient absorption through the intestinal lining as well as methods for the manufacture of and the use of these compositions for treating disorders including diabetes type II and clinical obesity that require a modulation of certain nutrients to the body.

Abstract: A systems and methods for determining a position of a medical tube within a patient is provided. In one example, systems and methods are provided for a self- detection positioning system that is capable of determining a location of a distal end of a medical tube placed within a patient, and notifying a physician of the location of the distal end of the medical tube.

Abstract: The systems and methods described herein related generally to a device that enables the directional control of flow through an anatomical tract of the body. More particularly, the device described herein includes a valve from a plurality of projections. In some implementations, the projections are configured as flaps, posts, or any combination thereof. In some implementations, the device is implanted into a patient's esophagus to prevent gastroesophageal reflux disease. The plurality of projections allow flow into a patient's stomach while substantially preventing a backflow of undesired fluids from the patient's stomach to the patient's esophagus.

Abstract: This disclosure relates to compositions including formulated sucralfate or other aluminum-crosslinked sulfated agents for the modulation of nutrient absorption through the intestinal lining as well as methods for the manufacture of and the use of these compounds for treating disorders requiring a modulation of certain nutrients to the body including diabetes type II and clinical obesity.

Abstract: The systems and methods described herein related generally to a device that enables the directional control of flow through an anatomical tract of the body. More particularly, the device described herein includes a valve from a plurality of projections. In some implementations, the projections are configured as flaps, posts, or any combination thereof. In some implementations, the device is implanted into a patient's esophagus to prevent gastroesophageal reflux disease. The plurality of projections allow flow into a patient's stomach while substantially preventing a backflow of undesired fluids from the patient's stomach to the patient's esophagus.